Quest Diagnostics (DGX) second-quarter EPS of $0.89 beat the Zacks Consensus Estimate by a penny and the year-ago quarter by 7 cents. However, revenues declined 1.4% to $1.9 billion, driven by a decline in both volume and pricing.
Meanwhile, the company proactively negotiated contracts with some MCOs at reduced prices. Although this gives more visibility, revenue per requisition was affected in the near term. Quest is adopting strategies such as suitable acquisitions, increased sales force and targeting additional geographies to drive its top line.
However, we believe in the near term volume and pricing outlook will remain under pressure unless economic scenario improves. As a result, we lower our estimates for the company and downgrade the stock to Underperform.